Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients
Retrieved on:
星期一, 十月 31, 2022
U.S. Securities and Exchange Commission, Safety, Queen Mary Hospital (Hong Kong), University, Annual report, HBV, University of Hong Kong, ChAdOx1, Private Securities Litigation Reform Act, Patient, OUI, SEC, Cancer, Oxford University Innovation, Immune system, Company, Security (finance), GLOBE, NASDAQ, Population, Autoimmunity, Vaccine, COVID-19, Queen, AstraZeneca, MVA, Hospital, HBsAg, Pharmaceutical industry, Vaccitech
HBV003 is a Phase 2b clinical trial designed to further evaluate the safety and efficacy of VTP-300 when combined with a low-dose anti-PD-1 antibody in patients with chronic hepatitis B infection.
Key Points:
- HBV003 is a Phase 2b clinical trial designed to further evaluate the safety and efficacy of VTP-300 when combined with a low-dose anti-PD-1 antibody in patients with chronic hepatitis B infection.
- VTP-300 includes Vaccitechs prime-boost platform, which utilizes 2 nonreplicating viral vectors, ChAdOx1 and MVA.
- Each viral vector encodes HBV antigens to elicit an immune response against HBV.
- We have been very encouraged by data emerging from our open-label HBV002 study, which shows that VTP-300 induced significant and sustained HBsAg declines in some patients with chronic HBV.